ReviewACS central science2026
Advancing Drug Discovery through Academia-Industry Collaborations: Lessons from Merck Discovery Chemistry Partnerships.
Review in ACS central science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Academia-industry partnerships are an important driver of innovation in drug discovery, and their success depends on intentional problem selection, effective resource sharing, and robust communication during project execution. This outlook highlights select Merck Sharp & Dohme Discovery Chemistry (MSD DC) collaborations reported over the past five years to illustrate principles that underpin productive academia-industry partnerships. Through representative case studies in synthesis collaborations, we illustrate two complementary collaboration strategies: targeted development of synthetic methods that address key medicinal chemistry bottlenecks, and capability-building efforts that enable technology transfer to accelerate drug discovery. We also highlight a few nonsynthetic collaborations by MSD DC in computational chemistry, structure elucidation, and chemical biology subfields, underscoring the cross-functional impact of these efforts on drug discovery. Beyond scientific advances, these collaborations also provide meaningful training and professional development opportunities for the next generation of chemists.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.